InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) has announced that Dr. Richard Toselli, President and CEO, will present at the 2021 H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will provide an overview of the company and key business updates. Attendees can access the webcast starting March 9, 2021, at 7:00 am ET on the company’s Investor Relations website. InVivo focuses on treating spinal cord injuries and was founded in 2005 with technology co-invented by notable figures in the biotechnology field.

Positive

• Participation in the prestigious H.C. Wainwright Global Life Sciences Conference highlights company visibility.
• Opportunity for one-on-one investor meetings enhances engagement and potential investment interest.

Negative

• None.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming 2021 H.C. Wainwright Global Life Sciences Conference. The conference is scheduled to be held March 9-10, 2021 in a virtual format. Dr. Toselli’s presentation will provide an overview of the company and highlight key business updates for the company.

A webcast of the presentation will be available on the Investor Relations - Events section of the InVivo website at https://investors.invivotherapeutics.com/events beginning March 9, 2021 at 7:00 am ET. In addition to the company’s presentation, Dr. Toselli and company management will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210305005052/en/

FAQ

What is the significance of InVivo Therapeutics presenting at the H.C. Wainwright Conference?

The presentation enhances the company's visibility and provides updates on its business and spinal injury treatment innovations.

When will the InVivo Therapeutics presentation take place?

The presentation is scheduled for March 9-10, 2021, at the H.C. Wainwright Global Life Sciences Conference.

How can I view the InVivo Therapeutics presentation?

The presentation will be available as a webcast on the company's Investor Relations website starting March 9, 2021, at 7:00 am ET.

Who is the CEO of InVivo Therapeutics?

Dr. Richard Toselli is the President and CEO of InVivo Therapeutics.

What does InVivo Therapeutics focus on?

InVivo Therapeutics specializes in research and development of treatments for spinal cord injuries.